Biogen (BIIB) Net Income - Minority (2009 - 2023)
Biogen (BIIB) recorded quarterly Net Income - Minority of $4.1 million in Q3 2023, down 35.94% quarter-over-quarter from $6.4 million in Q2 2023, and down 52.87% on a YoY basis from $8.7 million in Q3 2022.
Biogen (BIIB) Net Income - Minority (2009 - 2023) Analysis & Trends
Biogen's Net Income - Minority history runs 15 years deep, the most recent figure standing at $4.1 million for Q3 2023.
- In Q3 2023, Net Income - Minority fell 52.87% year-over-year to $4.1 million; the TTM figure through Sep 2023 stood at $4.1 million (down 52.87% YoY), while the FY2022 annual figure was $9.5 million, up 114.96% from the prior year.
- Net Income - Minority was $4.1 million for Q3 2023 at Biogen, down from $6.4 million in the prior quarter.
- In the past five years, Net Income - Minority ranged from a high of $21.6 million in Q1 2022 to a low of -$462.9 million in Q2 2021.
- Historically, Net Income - Minority has averaged -$42.8 million across 5 years, with a median of $8.7 million in 2022.
- The sharpest annual moves came in 2020 and 2021: Net Income - Minority jumped 375.61% in 2020, then slumped 3327.14% in 2021.
- A 5-year view of Net Income - Minority shows it stood at $4.1 million in 2019, then soared by 246.34% to $14.2 million in 2020, then tumbled by 547.18% to -$63.5 million in 2021, then soared by 114.96% to $9.5 million in 2022, then sank by 56.84% to $4.1 million in 2023.
- The last three Net Income - Minority figures came in at $4.1 million (Q3 2023), $6.4 million (Q2 2023), and $9.6 million (Q1 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 4.10 Mn |
| Jun 30, 2023 | 6.40 Mn |
| Mar 31, 2023 | 9.60 Mn |
| Dec 31, 2022 | 9.50 Mn |
| Sep 30, 2022 | 8.70 Mn |
| Jun 30, 2022 | 9.10 Mn |
| Mar 31, 2022 | 21.60 Mn |
| Dec 31, 2021 | -63.50 Mn |
| Sep 30, 2021 | -451.80 Mn |
| Jun 30, 2021 | -462.90 Mn |
| Mar 31, 2021 | 19.00 Mn |
| Dec 31, 2020 | 14.20 Mn |
| Sep 30, 2020 | 14.00 Mn |
| Jun 30, 2020 | 19.50 Mn |
| Mar 31, 2020 | 10.00 Mn |
| Dec 31, 2019 | 4.10 Mn |
| Sep 30, 2019 | 4.10 Mn |
| Jun 30, 2019 | 4.10 Mn |
| Mar 31, 2019 | 7.90 Mn |
| Dec 31, 2018 | 8.00 Mn |